Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder

Exclusion Criteria

• •Those who are first episode, drug naive MDD subjects
• •Those who have a current Axis I diagnosis of delirium, dementia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar 1 or 2 disorder, eating disorder, obsessive-compulsive disorder, panic disorder, or posttraumatic stress disorder
• •Those who have a clinically significant current Axis 2 diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder
• •Those who experience hallucinations, delusion, or any psychotic symptomatology in the current depressive episode
• •Those who have met DSM-IV-TR criteria for any significant substance use disorder within the past 12 months (except nicotine)
• •Those who have known allergy,hypersensitivity or previous unresponsiveness to aripiprazole or known intolerance to other study medications
• •Those who have had cognitive-behavioral therapy or other psychotherapy, or they have the potential need to be treated with them during the study periods
• •Those who are complicated with serious medical problem, such as severe renal, hepatic dysfunction, cardiovascular, lung, gastrointestinal, endocrine, nervous, infectious disease, or neoblastic, metabolic disease
• •Those who have shown previous unresponsiveness to adequate antidepressant trials more than 2 episodes or with 3 or more antidepressant treatments
• •Those who have chronic liver or renal disease
• •Those who are pregnant or brest-feeding
• •Those who have participated in a clinical trial with aripiprazole or any other investigational product within the past month(include randomized, double-blind, placebo-controlled or open-label study; but chart review,observational study can be enrolled)
• •Those who had a history of thyroid pathology, neuroleptic malignant syndrome, or serotonin syndrome
• •Those who have received adjunctive antipsychotic plus antidepressant for more than 3 weeks during the current episode
• •Those who have received electroconvulsive therapy for the current episode
• •Those who have shown an inadequate response to previous ECT in any episode
• •Those who have a suicidal risk
• •Those who are likely to require prohibited concomitant therapy during the trial
• •Those who have received treatment with a monoamine oxidase inhibitor within 2 weeks prior to enrollment